** Brokerage Jefferies says quarterly sales growth of Spravato, Johnson & Johnson's JNJ.N nasal spray for treatment-resistant depression, bodes well for psychedelic treatments
** JNJ reports Q1 sales of $320 million for Spravato, up 41.9% from a year earlier
** JNJ's commitment to building out infrastructure by working with hospitals or physicians and marketing the drug should only help facilitate adoption of future psychedelics, says Jefferies
** Brokerage says existing players in this space such as Atai Life Sciences 9VC.DE could "eventually leverage the global infrastructure built by JNJ"
** Atai's depression drug BPL-003 is currently in mid-stage development
** U.S.-listed shares of Atai ATAI.O up 3.3%
** Shares of Compass Pathways CMPS.O, which also has a psychedelic depression treatment in development, climbs 1.7%
** Including session's move, ATAI up 5.3%, CMPS down 18.8% YTD
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.